Welcome to HCPLive’s 5 Tales in Below 5—your fast, must-know recap of the highest 5 healthcare tales from the previous week, all in underneath 5 minutes. Keep knowledgeable, keep forward, and let’s dive into the most recent updates impacting clinicians and healthcare suppliers such as you!
Occupied with a extra conventional, textual content rundown? Check out the HCPFive!
Prime 5 Healthcare Headlines for Could 5- 11, 2025:
FDA Accepts Sparsentan (Filspari) sNDA for Focal Segmental Glomerulosclerosis
The FDA will assessment Travere Therapeutics’ utility for full approval of sparsentan in FSGS, with an advisory committee assembly deliberate forward of a January 2026 choice.
FDA Accepts BioCryst’s NDA for Berotralstat Oral Granules in Children With HAE
The FDA is evaluating berotralstat oral granules for pediatric hereditary angioedema, which may change into the primary oral preventive remedy for kids underneath 12.
SURMOUNT-5: Tirzepatide (Zepbound) Proves Benefit over Semaglutide (Wegovy) for Obesity
Tirzepatide demonstrated superior weight reduction outcomes in contrast with semaglutide within the SURMOUNT-5 trial for sufferers with weight problems.
Crinecerfont Reduces Steroid Use for Pediatric CAH in Phase 3 Analysis
Crinecerfont lowered steroid necessities whereas sustaining hormone management in kids with traditional congenital adrenal hyperplasia, no matter baseline traits.
Type 1 Diabetes Diagnosed in Adulthood Heightens Cardiovascular Risk
Adults identified with sort 1 diabetes face elevated cardiovascular and all-cause mortality dangers, no matter age at analysis, based on long-term nationwide information.
